Previous 10 | Next 10 |
Castle Biosciences(CSTL) announced that DecisionDx-Melanoma, the company's prognostic gene expression profile test for cutaneous melanoma, now utilizes an Integrated Test Result ((ITR)), designed to provide a more precise risk prediction in patients with stage I, II or III melanoma.DecisionDx...
Full-year 2020 revenues of $62.6 million, up 21% compared to 2019 Full-year 2020 dermatology test report volume up 8% compared to 2019 Full-year 2020 gross margin of 85% Earlier today, the Company launched Integrated DecisionDx-Melanoma Test Result, Utilizing A...
Newly validated i31-GEP algorithm integrates DecisionDx-Melanoma continuous score with clinicopathologic factors designed to provide a more precise, personalized likelihood of sentinel lymph node positivity Updated patient report also includes expanded dataset for risk of recu...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will release its financial results for the fourth quarter and year-ended December 31, 2020, after the clos...
Additional Virtual Posters Highlight Data on DecisionDx® DiffDx™-Melanoma and DecisionDx®-SCC Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today a...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced poster presentations with data on two of its skin cancer gene expression profile tests at the 18th Annual Winter C...
The following slide deck was published by Castle Biosciences, Inc. in conjunction with this event. For further details see: Castle Biosciences (CSTL) Investor Presentation - Slideshow
Castle Biosciences ([[CSTL]] -5.7%) announced preliminary performance results for 4Q20 and FY20.Delivered 18,185 gene expression profile test reports in 2020.Final, expanded LCD for CMS coverage for DecisionDx-Melanoma test became effective on Dec. 6, 2020. Since the effective date, more than...
Delivered 18,185 gene expression profile test reports in 2020 Year-end 2020 cash and cash equivalents were approximately $410 million Final, expanded LCD for CMS coverage for DecisionDx-Melanoma test became effective on Dec. 6, 2020 Launched two new skin cancer...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 23rd...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 44 th Annual Growth Conference on Tuesday, Aug. 13, 2024, at ...
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...